BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
Bristol Myers Squibb; Johnson & Johnson; Janssen; anticoagulant; Factor XIa inhibitor; BMS-986177; coronary trial; clinical trial termination
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
Merck; Cidara Therapeutics; CD388; antiviral; acquisition; influenza; phase 3; FDA Breakthrough Therapy; J&J; Sanofi; Keytruda
MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene
MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals
Gate Bioscience Captures $65M Series B to Advance Molecular Gate Protein Degradation Platform
Gate Bioscience; protein degradation; protein elimination therapeutics; Series B funding; Molecular Gates; Eli Lilly; Forbion; a16z Bio + Health; precision medicine; biotech innovation
Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns
Mikael Dolsten; Novo Nordisk; board of directors; withdrawal; personal reasons; Novo Nordisk Foundation; board shake-up; Danish pharma; Bavarian Nordic; chairman resignation
Diamyd Medical’s Pivotal Phase 3 Type 1 Diabetes Trial Clears Final Safety Review Ahead of Early Readout in March 2026
Diamyd Medical; Type 1 Diabetes; Phase 3 trial; DIAGNODE-3; safety review; Data Safety Monitoring Board (DSMB); interim readout; March 2026; HLA DR3-DQ2 genotype; Orphan Drug Designation; Fast Track Designation; accelerated approval pathway; precision therapy
Cylinder Health Appoints New Head of Gut-Brain Health and Expands Clinical Advisory Board
Cylinder Health; Gut-Brain Health; Clinical Advisory Board; Grace Niu; Dr. Hamed Khalili; Digital digestive health; GI care; Employee health
Zealand Pharma Pauses Development of GLP-1/GLP-2 Dual Agonist Dapiglutide for Obesity
Zealand Pharma; dapiglutide; GLP-1/GLP-2 dual agonist; obesity therapy; clinical development; obesity drug market; pipeline management; petrelintide; survodutide
Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data
Korro Bio; KRRO-110; Alpha-1 Antitrypsin Deficiency (AATD); RNA editing; clinical trial failure; layoffs; Novo Nordisk partnership; GalNAc platform; biotech strategy shift